Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
It is intended for contrast enhancement in MRI scans
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated